Hologic, Inc. (NASDAQ:HOLX) Expected to Announce Earnings of $0.70 Per Share

Analysts forecast that Hologic, Inc. (NASDAQ:HOLXGet Rating) will announce earnings per share (EPS) of $0.70 for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Hologic’s earnings, with the highest EPS estimate coming in at $0.72 and the lowest estimate coming in at $0.67. Hologic posted earnings of $1.33 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 47.4%. The business is expected to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Hologic will report full-year earnings of $5.49 per share for the current year, with EPS estimates ranging from $5.10 to $5.63. For the next financial year, analysts expect that the business will report earnings of $3.68 per share, with EPS estimates ranging from $3.41 to $4.00. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Hologic.

Hologic (NASDAQ:HOLXGet Rating) last announced its quarterly earnings data on Wednesday, April 27th. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $1.55 by $0.52. The business had revenue of $1.44 billion during the quarter, compared to analyst estimates of $1.28 billion. Hologic had a return on equity of 42.26% and a net margin of 28.79%. During the same quarter last year, the firm posted $2.59 earnings per share.

HOLX has been the topic of several recent research reports. Morgan Stanley cut their price target on Hologic from $76.00 to $75.00 and set an “equal weight” rating on the stock in a research note on Thursday, February 3rd. Raymond James cut their target price on Hologic from $88.00 to $84.00 and set an “outperform” rating on the stock in a research note on Thursday, February 3rd. Wells Fargo & Company lowered Hologic from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $90.00 to $75.00 in a research report on Monday, April 25th. Citigroup cut their price objective on shares of Hologic from $78.00 to $75.00 in a research report on Thursday, April 28th. Finally, StockNews.com started coverage on shares of Hologic in a report on Thursday, March 31st. They issued a “buy” rating for the company. Five analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $79.00.

Shares of HOLX opened at $74.27 on Friday. Hologic has a fifty-two week low of $60.10 and a fifty-two week high of $81.04. The firm’s 50-day simple moving average is $74.48 and its two-hundred day simple moving average is $73.40. The stock has a market cap of $18.52 billion, a PE ratio of 12.24, a price-to-earnings-growth ratio of 0.86 and a beta of 1.09. The company has a debt-to-equity ratio of 0.59, a quick ratio of 2.57 and a current ratio of 2.97.

In other news, insider Sean S. Daugherty sold 2,179 shares of Hologic stock in a transaction that occurred on Thursday, February 24th. The shares were sold at an average price of $71.14, for a total value of $155,014.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.54% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. lifted its holdings in Hologic by 2.5% in the fourth quarter. BlackRock Inc. now owns 21,888,278 shares of the medical equipment provider’s stock valued at $1,675,766,000 after acquiring an additional 532,526 shares during the period. State Street Corp lifted its stake in shares of Hologic by 3.9% in the 4th quarter. State Street Corp now owns 11,332,073 shares of the medical equipment provider’s stock worth $867,584,000 after purchasing an additional 423,495 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Hologic by 7.4% in the fourth quarter. Geode Capital Management LLC now owns 5,790,351 shares of the medical equipment provider’s stock worth $442,486,000 after buying an additional 398,923 shares during the last quarter. Parnassus Investments LLC grew its position in Hologic by 0.7% during the third quarter. Parnassus Investments LLC now owns 4,142,799 shares of the medical equipment provider’s stock valued at $305,780,000 after buying an additional 26,894 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in Hologic by 29.6% during the first quarter. JPMorgan Chase & Co. now owns 3,424,059 shares of the medical equipment provider’s stock valued at $263,039,000 after buying an additional 781,084 shares during the last quarter. Hedge funds and other institutional investors own 92.70% of the company’s stock.

About Hologic (Get Rating)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

Read More

Get a free copy of the Zacks research report on Hologic (HOLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.